Arctic Bioscience - Clinical Trial Application for HRO350 Phase IIb submitted

10 Oct 2022 07:57 CEST

Reference is being made to the stock exchange release from 3 October 2022 where
Arctic Bioscience gave a status update related to the submission of the Clinical
Trial Application (CTA) for a Phase IIb clinical trial in mild-to-moderate
psoriasis with the investigational medicinal product (IMP) HRO350.

Arctic Bioscience is pleased to announce that the CTA has been submitted.
Approval of CTA by authorities will allow for the first patient to be enrolled
in the Phase IIb clinical trial as planned in Q4 2022. Sites for the clinical
trial with access to sufficient number of patients to conduct the studies are
localized in five European countries.

"We are pleased that the CTA has been submitted. This is an important step in
our drug development journey and vital for the HRO350 Phase IIb clinical trial",
says Christer L. Valderhaug, CEO of Arctic Bioscience.

The CTA contains key information about the IMP HRO350 and the planned clinical
trial activities.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Christer L. Valderhaug

CEO of Arctic Bioscience AS

Mobile: +47 920 84 601

Email: christer@arctic-bioscience.com

Jone R. Slinning

CFO of Arctic Bioscience AS

Mobile: +47 948 75 469

Email: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a team of highly competent people with experience in
developing marine oils and experience from global pharmaceutical companies.

More information:
Access the news on Oslo Bors NewsWeb site